PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
Public ClinicalTrials.gov record NCT00274599. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group, Multicentre, Forced-Titration, 14-Week Treatment Study Comparing MICARDIS® (Telmisartan 40-80-80 mg, QD) and ALTACE® (Ramipril 2.5-5-10 mg, QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg \& 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases.
Study identification
- NCT ID
- NCT00274599
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 812 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 19 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2002 (Actual)
- Primary completion
- Nov 30, 2003 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 6, 2023
Started 2002
United States locations
- U.S. sites
- 43
- U.S. states
- 25
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| Harold B. Betton, M.D. | Little Rock | Arkansas | — | — |
| Attn: Ginger Paselk | Long Beach | California | — | — |
| Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| Boehringer Ingelheim Investigational Site | Orange | California | — | — |
| Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| Boehringer Ingelheim Investigational Site | Santa Ana | California | — | — |
| Boehringer Ingelheim Investigational Site | Santa Rosa | California | — | — |
| Boehringer Ingelheim Investigational Site | Vista | California | — | — |
| Boehringer Ingelheim Investigational Site | Hamden | Connecticut | — | — |
| Boehringer Ingelheim Investigational Site | Daytona Beach | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Melbourne | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Marietta | Georgia | — | — |
| Boehringer Ingelheim Investigational Site | Boise | Idaho | — | — |
| Boehringer Ingelheim Investigational Site | Meridian | Idaho | — | — |
| Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| Boehringer Ingelheim Investigational Site | Orland Park | Illinois | — | — |
| GFI Pharmaceuticals | Evansville | Indiana | — | — |
| Boehringer Ingelheim Investigational Site | Newton | Kansas | — | — |
| Boehringer Ingelheim Investigational Site | Wichita | Kansas | — | — |
| Boehringer Ingelheim Investigational Site | Metairie | Louisiana | — | — |
| Boehringer Ingelheim Investigational Site | Auburn | Maine | — | — |
| Boehringer Ingelheim Investigational Site | Moorestown | New Jersey | — | — |
| Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| Boehringer Ingelheim Investigational Site | East Syracuse | New York | — | — |
| Boehringer Ingelheim Investigational Site | White Plains | New York | — | — |
| Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| Boehringer Ingelheim Investigational Site | Levittown | Pennsylvania | — | — |
| Boehringer Ingelheim Investigational Site | Anderson | South Carolina | — | — |
| Spartanburg Medical Research | Spartanburg | South Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| R/D Clinical Research, Inc. | Lake Jackson | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| Boehringer Ingelheim Investigational Site | Lacey | Washington | — | — |
| Boehringer Ingelheim Investigational Site | Lakewood | Washington | — | — |
| Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
| Boehringer Ingelheim Investigational Site | Charleston | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00274599, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2023 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00274599 live on ClinicalTrials.gov.